[1]张 玲.生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证的临床效果[J].医学信息,2021,34(14):169-171.[doi:10.3969/j.issn.1006-1959.2021.14.048]
　ZHANG Ling.Clinical Effect of Shengmaisan and Xuefu Zhuyu Decoction in Treating Coronary Heart Disease with Qi and Yin Deficiency and Blood Stasis Syndrome[J].Medical Information,2021,34(14):169-171.[doi:10.3969/j.issn.1006-1959.2021.14.048]
点击复制

生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证的临床效果()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年14期
页码:
169-171
栏目:
中医中药
出版日期:
2021-07-15

文章信息/Info

Title:
Clinical Effect of Shengmaisan and Xuefu Zhuyu Decoction in Treating Coronary Heart Disease with Qi and Yin Deficiency and Blood Stasis Syndrome
文章编号:
1006-1959（2021）14-0169-03
作者:
张 玲
（天峨县人民医院内科/中医科，广西 天峨 547300）
Author(s):
ZHANG Ling
(Department of Internal Medicine/Department of Traditional Chinese Medicine,Tian’e County People’s Hospital, Tian’e 547300,Guangxi,China)
关键词:
生脉散; 血府逐瘀汤; 冠心病; 气阴两虚血瘀证
Keywords:
Shengmaisan; Xuefu zhuyu decoction; Coronary heart disease; Qi and yin deficiency and blood stasis syndrome
分类号:
R256.2
DOI:
10.3969/j.issn.1006-1959.2021.14.048
文献标志码:
A
摘要:
目的 观察生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证临床疗效。方法 选取2019年9月~2020年9月在我院诊治的64例冠心病气阴两虚血瘀证患者为研究对象，采用随机数字表法分为对照组和观察组，各32例。对照组采用西药治疗，观察组在对照组基础上联合生脉散合血府逐瘀汤治疗；比较两组治疗总有效率、中医证候评分、心功能指标、BNP水平、MLHFQ评分及不良反应发生情况。结果 观察组治疗总有效率（93.75%）高于对照组（81.25%），差异有统计学意义（P＜0.05）；观察组心悸、气短、乏力、口渴评分均低于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组LVEF、ΔFS、E/A均高于对照组，LVEDD小于对照组，差异有统计学意义（P＜0.05）；两组BNP水平均低于治疗前，MLHFQ评分高于治疗前，且观察组BNP水平低于对照组，MLHFQ评分高于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证效果确切，可提高治疗效果，改善临床症状，促进心功能恢复，安全性良好。
Abstract:
Objective To observe the clinical efficacy of Shengmai Powder and Xuefu Zhuyu Decoction in the treatment of coronary heart disease with Qi and yin deficiency and blood stasis syndrome.Methods 64 patients with coronary heart disease with deficiency of qi and yin and blood stasis syndrome who were diagnosed and treated in our hospital from September 2019 to September 2020 were selected as the research objects. They were divided into control group and observation group by random number table, with 32 cases in each group.The control group was treated with western medicine, and the observation group was combined with Shengmaisan and Xuefu Zhuyu Decoction on the basis of the control group;The total effective rate of treatment, TCM syndrome score, heart function index, BNP level, MLHFQ score and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group (93.75%) was higher than that in the control group (81.25%),the difference was statistically significant (P<0.05);The scores of palpitations, shortness of breath, fatigue, and thirst in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05);After treatment, LVEF, ΔFS, E/A in the observation group were higher than those in the control group, and LVEDD was lower than the control group, the difference was statistically significant (P<0.05);The BNP level of the two groups was lower than before treatment, the MLHFQ score was higher than that before treatment, and the BNP level of the observation group was lower than that of the control group, and the MLHFQ score was higher than that of the control group, the difference was statistically significant (P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Shengmaisan combined with Xuefu Zhuyu Decoction is effective in treating coronary heart disease with Qi and yin deficiency and blood stasis syndrome. It can improve the therapeutic effect, improve clinical symptoms, promote the recovery of heart function, and has good safety.

参考文献/References:

[1]邢小燕,翟向伟,范辉,等.血府逐瘀汤联合西药治疗心血瘀阻型冠心病心绞痛疗效观察[J].陕西中医,2017,38(10):1368-1369. [2]刘湘杰,程丑夫,刘思弘.生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证临床观察[J].湖南中医药大学学报,2017,37(4):423-425. [3]尹雁,王伟,王俊尧,等.冠心病心绞痛合并高脂血症患者气滞血瘀痰阻证和气阴两虚痰阻证相关血清蛋白比较分析[J].辽宁中医药大学学报,2018,20(4):83-85. [4]于忠,王伟.冠心病患者冠脉CTA 表现及与中医辨证分型相关性研究[J].新中医,2019,51(3):16-18. [5]王阶,陈光.基于复杂系统的冠心病痰瘀滞虚理论及临证应用[J].中国实验方剂学杂志,2019,25(1):11-15. [6]刘湘杰,程丑夫,刘思弘.生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证临床观察[J].湖南中医药大学学报,2017,37(4):423-425. [7]郭炳利.血府逐瘀汤加味治疗冠心病劳累性心绞痛疗效观察[J].安徽卫生职业技术学院学报,2016,15(2):138-139. [8]谭万江.辛伐他汀联合生脉散合血府逐瘀汤治疗冠心病的疗效分析[J].中国现代应用药学,2020,37(4):98-102. [9]李春红.生脉散合补阳还五汤加减治疗冠心病稳定型心绞痛32例临床观察[J].中国中医药科技,2014,21(6):703. [10]许晓梅.血府逐瘀汤治疗冠心病心肌缺血患者的临床观察[J].中国中医药现代远程教育,2017,5(16):98-100. [11]王涛,王世钦,毕淑霞.生脉散合血府逐瘀汤治疗慢性心力衰竭(气阴两虚、心血瘀阻证)临床观察[J].中国中医急症,2014,23(10):1917-1918. [12]周加信.生脉散加味治疗冠心病心绞痛33例临床观察[J].齐齐哈尔医学院报,2015,36(7):1026-1027. [13]赵毅,王以新.升降散合血府逐瘀汤治疗气滞血瘀型冠心病[J].吉林中医药,2014,34(10):1053-1054,1080. [14]寇晓忱,刘悦,张哲,等.从脾虚论治冠心病中医文献评析[J].辽宁中医药大学学报,2015,17(3):140-142. [15]马骏,范辉.生脉散合血府逐瘀汤加减治疗老年气虚血瘀型阵发性心房纤颤的临床研究[J].现代中西医结合杂志,2018,27(29):3209-3212.

相似文献/References:

[1]宫丽萍.血府逐瘀汤加减治疗气滞血瘀型冠心病心绞痛的疗效研究[J].医学信息,2018,31(12):145.[doi:10.3969/j.issn.1006-1959.2018.12.046]
　GONG Li-ping.Therapeutic Effect of Xuefu Zhuyu Decoction on Angina Pectoris with Qi Stagnation and Blood Stasis[J].Medical Information,2018,31(14):145.[doi:10.3969/j.issn.1006-1959.2018.12.046]
[2]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Medical Information,2019,32(14):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[3]李 娟,胡 欣,张小妹.米非司酮联合血府逐瘀汤治疗子宫腺肌病的临床观察[J].医学信息,2021,34(23):168.[doi:10.3969/j.issn.1006-1959.2021.23.051]
　LI Juan,HU Xin,ZHANG Xiao-mei.Clinical Observation of Mifepristone Combined with Xuefu Zhuyu Decoction in the Treatment of Adenomyosis[J].Medical Information,2021,34(14):168.[doi:10.3969/j.issn.1006-1959.2021.23.051]
[4]于 静,陈丽云.血府逐瘀汤治疗心力衰竭的文献计量分析[J].医学信息,2023,36(09):16.[doi:10.3969/j.issn.1006-1959.2023.09.003]
　YU Jing,CHEN Li-yun.Bibliometric Analysis of Xuefu Zhuyu Decoction in the Treatment of Heart Failure[J].Medical Information,2023,36(14):16.[doi:10.3969/j.issn.1006-1959.2023.09.003]
[5]谭晓君,杨心怡,张雪杨,等.生脉散对H2O2损伤PC12细胞保护作用的研究[J].医学信息,2023,36(11):86.[doi:10.3969/j.issn.1006-1959.2023.11.015]
　TAN Xiao-jun,YANG Xin-yi,ZHANG Xue-yang,et al.Study on the Protective Effect of Shengmai-san on PC12 Cells Damaged by H2O2[J].Medical Information,2023,36(14):86.[doi:10.3969/j.issn.1006-1959.2023.11.015]
[6]陈沫良,王晓珍,许光辉,等.基于网络药理学和SPR检测探讨生脉散治疗2型糖尿病合并冠心病的作用机制[J].医学信息,2024,37(20):1.[doi:10.3969/j.issn.1006-1959.2024.20.001]
　CHEN Moliang,WANG Xiaozhen,XU Guanghui,et al.Mechanism of Shengmaisan in Treating Type 2 Diabetes Mellitus with Coronary Heart Disease Based on Network Pharmacology and SPR Assay[J].Medical Information,2024,37(14):1.[doi:10.3969/j.issn.1006-1959.2024.20.001]

更新日期/Last Update: 1900-01-01